Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease
Background: The goal of the treatment of Alport syndrome (AS) is to delay the progression of kidney damage. The current standard of care is the use of Renin Angiotensin Aldosterone System (RAAS) blockers: angiotensin-converting enzyme inhibition (ACEi), angiotensin receptor blockade, and, recently,...
Enregistré dans:
Auteurs principaux: | Antonio Mastrangelo, Marta Brambilla, Giorgia Romano, Jessica Serafinelli, Giuseppe Puccio, Marisa Giani, Giovanni Montini |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f56ab12d38da4ab0be4855d55fa3c3b5 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Menores niveles tisulares de la enzima convertidora de angiotensina I homologa (ECA-2) y angiotensina-(1-9) están asociados a mayor remodelamiento de la pared aórtica de ratas hipertensas
par: Ocaranza,María Paz, et autres
Publié: (2010) -
The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
par: O. K. Vikulova, et autres
Publié: (2020) -
2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
par: Luigi Cappannoli, et autres
Publié: (2020) -
Measurement of serum ACE status may potentially improve the diagnosis of SARS-CoV-2 infection
par: Gcinokwakhe D Ngcobo
Publié: (2021) -
Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
par: David S. Fedson, et autres
Publié: (2020)